Sigyn Therapeutics (Sigyn Therapeutics) Ending Cash Position : $0.03 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Ending Cash Position?

Sigyn Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $0.03 Mil.

Sigyn Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 ($0.07 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Mar. 2024 ($0.03 Mil).

Sigyn Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($0.34 Mil) to Dec. 2022 ($0.01 Mil) but then increased from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil).

Sigyn Therapeutics Ending Cash Position Historical Data

The historical data trend for Sigyn Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Ending Cash Position Chart

Sigyn Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

0.08

0.34

0.01

Sigyn Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															0.32	0.02	0.07	0.01	0.03

Sigyn Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sigyn Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.008	+	0.004
	=	0.01

Sigyn Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.012	+	0.021
	=	0.03

Sigyn Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sigyn Therapeutics (Sigyn Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106

Website

https://www.sigyntherapeutics.com

Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.

Executives

Joseph Segelman	director, 10 percent owner, officer: President & CEO	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp	10 percent owner	9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman	director, officer: Secretary	9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212